Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Zacks Research

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday, Zacks reports.

SUPN has been the subject of several other research reports. Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $67.00 to $87.00 and gave the company an “overweight” rating in a research report on Wednesday. Jefferies Financial Group began coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday. They issued a “strong-buy” rating on the stock. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Piper Sandler initiated coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday. They set an “overweight” rating and a $47.00 target price for the company. Finally, Weiss Ratings lowered shares of Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Supernus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $63.50.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $28.21 on Tuesday. The stock has a market cap of $3.33 billion, a PE ratio of 7.88 and a beta of 0.84. Supernus Pharmaceuticals has a one year low of $26.74 and a one year high of $42.81. The stock has a fifty day moving average of $41.74 and a 200 day moving average of $47.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). The firm had revenue of $208.60 million during the quarter, compared to the consensus estimate of $217.56 million. Supernus Pharmaceuticals had a net margin of 32.75% and a negative return on equity of 418.04%. The firm’s revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.80) EPS. As a group, sell-side analysts predict that Supernus Pharmaceuticals will post 3.66 EPS for the current fiscal year.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Supernus Pharmaceuticals during the second quarter worth about $434,871,000. Bank of America Corp DE raised its stake in Supernus Pharmaceuticals by 37.2% during the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after purchasing an additional 193,479 shares during the period. Ashford Capital Management Inc. lifted its holdings in Supernus Pharmaceuticals by 5.4% in the 1st quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock worth $33,360,000 after purchasing an additional 32,843 shares in the last quarter. Rice Hall James & Associates LLC purchased a new position in Supernus Pharmaceuticals in the 2nd quarter worth approximately $22,800,000. Finally, Pictet Asset Management Holding SA lifted its holdings in Supernus Pharmaceuticals by 0.6% in the 3rd quarter. Pictet Asset Management Holding SA now owns 434,915 shares of the specialty pharmaceutical company’s stock worth $19,116,000 after purchasing an additional 2,437 shares in the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

More Supernus Pharmaceuticals News

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $87 and maintained an “overweight” rating, signaling substantial potential upside in the firm’s view. However, the target may not reflect the completed merger or subsequent listing changes. Cantor Fitzgerald rating information
• Positive Sentiment: Recent commentary describes SUPN as potentially undervalued, citing ONAPGO’s exclusivity and the combined company’s prospects. These are valuation arguments, not company guidance. Supernus after its Indivior merger looks undervalued Supernus may be undervalued after ONAPGO exclusivity
• Positive Sentiment: One report highlights $473 million in shareholder payouts, a potentially favorable one-time return of capital. Supernus sends $473 million to shareholders
• Neutral Sentiment: Supernus completed its merger with Indivior, creating a CNS-focused biopharmaceutical company. The combination could broaden the business, but investors will assess the merged company’s prospects and integration. Supernus completes merger with Indivior
• Negative Sentiment: The merger and reported Nasdaq delisting raise uncertainty for investors holding SUPN: the shares may no longer trade as a standalone Nasdaq-listed security, limiting the relevance of older SUPN targets and comparisons. Changes after Supernus’s Nasdaq delisting and merger

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.